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Available online xxxxGlobal burden disease studies point out that one of the top cause-specific anemias is iron deficiency (ID). Recent
advances in knowledge of ironhomeostasis have shown that fragile patients are a new target population inwhich
the correction of ID might impact their morbidity, mortality and quality of life. We did a systematic review using
specific search strategy, carried out the review of PubMed database, Cochrane Database of systemic reviews and
international guidelines on diagnosis and clinical management of ID from 2010 to 2016. The International guide-
lineswere limited to thosewith peer–review process and published in journal present in citation index database.
The eligible studies show that serum ferritin and transferrin saturation are the key tests in early decision-making
process to identify iron deficiency anemia (IDA). The clinician has to carefully consider fragile and high-risk sub-
set of patients such as elders or individualswith chronic diseases (i.e chronic kidney disease, inflammatory bowel
disease, chronic heart failure). Treatment is based on iron supplementation. Infusion route should be preferen-
tially considered in frail patients especially in the view of new iron available formulations. The available evi-
dences indicate that (i) recurrent IDA should always be investigated, considering uncommon causes; (ii) IDA
might worse the performance and the clinical outcome of fragile and high-risk patients and require an intensive
treatment.
© 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.Keywords:
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CHF1. Background
Studies of global burden diseases (GBD 2010) have pointed out that
anemia is a growing problem of public health also in well-developed
Countries [1,2]. In both sexes, the main causes of anemia identified by
GBD are iron deficient anemias (IDA), thalassemias, sickle cell disease
and infection related anemias, such as malaria, schistosomiasis or
hoockwarm [1,2]. IDA andβ-thalassemias are the top two cause-specific
anemia burden and both of them are characterized by microcytosis. By
excluding inherited red cells disorders, iron deficiency (ID) seems to
be the main cause of increased years life lived with disability (YLD) ob-
served in all ages and in both sex by GBD 2010 studies. This results in
low patient quality of life (QoL) and increase risk of developing severe
organ complications with growing cost for National health systems
[3]. Furthermore, IDA affects a large part of adult and elderly patients
admitted to Internal Medicine Units. The precocious and correct identi-
fication of the cause(s) underlying IDA as well as the specificicine, University ofMilan, IRCCS,
llini).
cine. Published by Elsevier B.V. All rig
et al, Clinical management o
017), http://dx.doi.org/10.10therapeutic intervention are crucial to impact YLD and patients QoL.
Here, we review the advances in pathogenesis, diagnosis, treatment
and areas of uncertainty in IDA in adults from January 2010 toDecember
2016.
2. Methods
The present panel of Authors, using specific search strategy, carried
out the review of PubMed database, Cochrane Database of systemic re-
views and international guidelines on diagnosis and clinical manage-
ment of ID from 2010 to 2016. The International guidelines were
limited to those with peer–review process and published in journal
present in citation index database. The main following search terms
were used: microcytic anemia, iron deficiency, iron deficiency anemia,
occult bleeding, nutritional deficiency diagnosis, treatment(s). We
established the following exclusion criteria for studies to be analyzed:
subjects b18 years-old, pregnant women, maternal hemorrhage and
breast-feeding. We screened 7264 titles, a total of 195 articles were
manually reviewed and 58 were selected as relevant (Fig. 1S). We ex-
cluded opinion articles, case series, commentaries; whereas we focused
randomized clinical trials, meta-analysis, systematic reviews, clinicalhts reserved.
f iron deficiency anemia in adults: Systemic review on advances in
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were discussed within the panel.3. Results
3.1. Major advances in pathogenesis of ID
IDA is a microcytic anemia, which defines a decrease mean red cell
volume (MCV) as a consequence of reduced hemoglobin (Hb) produc-
tion. This seems to be related to the absence of negative control of Hb
concentration on mitotic processes of late stage erythroblasts [4–6]. ID
with or without anemia accounts for approximately 80% of
microcytosis; whereas, rare inherited defects of ironmetabolism, of glo-
bin chains andheme synthesis account globally for almost 20% ofmicro-
cytic anemias [6,7].
Recent studies suggest that an optimal iron homeostasis is the main
driver of normal erythropoiesis. Iron metabolism is highly and finely
regulated by multiple crossing pathways, which contribute to the iron
recycling after red cell destruction by the reticuloendothelial system
aswell as the absorption of 1mg of iron from nutrition sources. This en-
sures the availability of 25mg of iron, required for normal red cell daily
production [8–10].
Molecular and functional studies have identified different proteins
involved in iron metabolism such as the iron membrane transporters
(DMT1 and ferroportin) located on enterocytes, the iron reductase en-
zyme required for Fe bivalent-trivalent modification, the plasma iron
transporters and cell storage (transferrin and ferritin) and iron control-
ler (IRP1 and IRP2 HFE, hepcidin) [10,11]. Among the novel identified
systems, hepcidin (Hamp) represents a crucial actor in ironmetabolism
and it is the major controller of iron levels in the body. It is produced by
liver cells and acts on ferroportin, causing its internalization and de-
struction. Iron overload and inflammatory states stimulate Hamp gene
expression; whereas, anemia, iron deficiency and stressed erythropoie-
sis repress Hamp [6].
Plasma iron levels regulate Hamp production by transferrin, which,
on binding iron, serves as a ligand for two hepatocellular receptors:
transferrin receptor 1 (TfR1) and 2 (TfR2). These crosstalk with a
matriptase named transmembrane protease serine 6 (TMPRSS6),
which participates to pathways involved in Hamp expression. Muta-
tions in TMPRSS6 gene cause severe microcytic anemias [6,11–13].Fig. 1. Proposed algorithm for diagnose and treatment of iron deficiency anemia. MCV: mean c
blood cells; SF: serum ferritin: TST: transferrin saturation; ID: iron deficiency; IDA: iron deficie
receptor; CRP: C reactive protein; Hamp: hepcidin; pts.: patients; CKD: chronic kidney disea
occult bleeding; IRIDA: iron refractory iron deficiency anemia; inflamm.: inflammatory.
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A clinician approaching a subjectwithmild to severemicrocytic ane-
mia should always begin by patient’ s history (timing of the appearance
of symptomsof anemic syndrome) andby askingwhether previous iron
supplementation (which type, how long and howmany times over the
last 2–3 years) has been already prescribed. In their making-decision
process, clinicians have to carefully consider fragile and high-risk subset
of patients such as elders or individuals with chronic diseases affected
by CKD, IBD or HD (Fig. 1).
Microcytic anemia is defined by MCV b 80 fL, hypochromic red cells
N 6% orMCH b 25 g/dL and reticulocyte hemoglobin content-CHr b 29pg
(Table 1; Fig. 1) [3,14,15]. International guidelines agree on key blood
tests to be carried out for the diagnosis of IDA [3,16]. Up to now serum
ferritin and transferrin saturation are the key tests in early decision-
making process to identify IDA. Marker of inflammation such as CRP
has to be evaluated in order to exclude a possible co-existing chronic in-
flammation disease. Based on these parameters, we identified (i) an ab-
solute iron deficiency, when the total body iron stores are depleted; and
(ii) a functional iron deficiency, when the body iron mobilization is al-
tered and does not meet the iron demand for the erythropoiesis [17].
Soluble transferrin receptor (sTfR) and sTfR-ferritin index (sTfr-F)
have been proposed as complementary parameters to identify IDA in
presence of possible confounding factors such inflammation that affects
serum ferritin levels (Table 1) [5,17–20]. In addition, the determination
of Hamp serum levels may be another interesting new tool in diagnosis
of iron refractory iron deficiency anemia (IRIDA) or in presence of con-
founding factors such as inflammation (Table 1). However, their use is
still limited due to the lack of studies on large population and of interna-
tional standardization threshold transferable to clinical routine process-
es [5,17–22].
3.3. Work-up for diagnosis of IDA in patients in internal medicine setting
Starting frommicrocytosis, we developed an algorithm for diagnosis
of ID/IDA based on serum ferritin levels (SF) and percentage transferrin
saturation (TST) combined with rigorous analysis of patient history. As
shown in Fig. 1, the initial evaluation step of a patientwith hypochromic
microcytic anemia is to exclude the possible presence of β-thalassemic-
trait, especially for the subjects in/from endemic areas. Using SF and TST
values, we identified three subsets of subjects withmicrocytic anemias:ell volume; MCH: mean cell hemoglobin, CHr: reticulocyte hemoglobin content; RBCs: red
ncy anemia; Suppl.: supplementation: Fe: iron; Hb: hemoglobin; sTfr: soluble transferrin
se; IBD: inflammatory bowel disease; CHF: chronic heart failure; GIob: gastrointestinal
f iron deficiency anemia in adults: Systemic review on advances in
16/j.ejim.2017.04.018
Table 1
Microcytic anemia: main causes and screening tests.
Nutritional deficiency Absorption deficiency IRIDA ACD β-Thalassemic trait
RBCs (cells/uL)
Hb (g/dL)
MCV (fL)
Reticulocytes (cells/uL)
CHr (g/dL)
CRP (mg/dL)
%Transferrin saturation
Ferritin (ng/mL) variable
RBCs: red blood cells; Hb: hemoglobin;MCV:mean cell volume; CHr: reticulocyte hemoglobin content; CRP: C reactive protein; IRIDA: iron refractory irondeficiency anemia; ACD: anemia
of chronic disease.
3L. De Franceschi et al. / European Journal of Internal Medicine xxx (2017) xxx–xxxpatients with (1) SF N 100 μg/L and TST 20–50%; (2) SF N 100 μg/L and
TST b 20%; (3) SF b 30 μg/L and TST b 20% (Fig. 1). To identify the pres-
ence of IDA within the first two groups characterized by SF N 100 μg/L,
we suggest to measure CRP levels, to define whether there is an under-
lying active chronic inflammatory disease. TST helps in dissecting func-
tional ID from IDA especially in this subset of patients (Fig. 1). IDA is
recognized in patients with either SF ≥ 100 μg/L and TST b 20% (IDA in
chronic inflammatory disease) or SF b 30 μg/L and TST b 20%. The fol-
lowing step is to define the timing and the possible recurrence of IDA
(Fig. 1). In a new diagnosis of IDA, patient fragility is important to be
identified in order to offer the more effective therapeutic approach
(Fig. 1). Based on the revision of the literature, fragile patients are de-
fined as subjects with: chronic kidney disease and/or chronic heart fail-
ure and/or elderly [3,5,23–29]. In these, we propose hemoglobin (Hb)
levels to be used in treatment choice (Fig. 1).
In recurrent IDA, a careful collection of patient history will help in
defining whether it is a recurrent explained IDA or an unexplained
IDA (Fig. 1). Concerning the recurrent explained IDA, the following
causes should be always investigated: (i) original cause of IDA; (ii) pa-
tient adherence to the iron supplementation; (iii) length of iron supple-
mentation; (iv) adverse events related to iron supplementation (i.e. GI
symptoms) (Fig. 1).
In presence of unexplained recurrent IDA, physician should consider
(i) gastrointestinal disorders such as autoimmune gastritis, chronic in-
fection by Helicobacter pylori or Giardia lambia; or (ii) hereditary disor-
ders of iron metabolism such as iron resistant iron deficient anemia
(IRIDA) (Fig. 1).
The detail approaches to special subset of patients is discussed in the
following paragraphs.
3.3.1. Chronic renal disease (CKD)
Microcytic anemia might increase the biocomplexity of anemia in
patients with end-stage chronic renal disease (CKD) (Fig. 1, Table 2)
[30,31]. In fact, the inadequate production of erythropoietin might be
further aggravated by ID, which contributes to hypo-responsiveness to
erythropoiesis of stimulating agents (EASs). The occurrence of ID in
CKD with the appearance of microcytic anemia is mainly related to dif-
ferent synergizing factors: (i) reduced intestinal iron absorption and (ii)
chronic inflammatory state [32–35]. The diagnosis of IDA in CKD is
based on serum ferritin levels and transferrin saturation percentage
(Table 2). In addition, the percentage of hypochromic red cells (N6%)
and reticulocyte hemoglobin content-CHr (b29 pg) might be useful
tools in treatment and follow-up of CKD patients with IDA [34,36].
3.3.2. Chronic heart failure (CHF)
Growing evidences indicate that ID is an important novel comorbid-
ity of chronic heart failure (CHF) with or without microcytic anemia
(Fig. 1, Table 2). Since subjects with CHF might be considered as fragile
patients, they require special attention. In CHF, twomain factors sustain
ID: patients aging and chronic inflammation state due to failing heart
function, which affects Hamp system and increases ferritin levels [28,Please cite this article as: De Franceschi L, et al, Clinical management o
diagnosis and treatment, Eur J Intern Med (2017), http://dx.doi.org/10.1037–42]. Different studies have shown that the prevalence of ID increases
with heart failure severity, most likely related to the cumulative effects
of different mechanisms: (i) worsening chronic inflammatory state; (ii)
anorexia; (iii) GI mucosal oedema and decreased gastric and intestinal
motility; (iv) decreased mesenteric blood flow and (v) frequent blood
tests [42–44]. The recent observation of increased rate of hospital re-ad-
mission for CHF patients compared to individuals with CHF without ID,
strongly support the impact of ID/and or IDA on CHF [28,29,45–47].
Thus, in CHF patients, the identification and correction of ID/IDA should
be considered as part of comprehensive clinical management of CHF.
3.3.3. Elderly patients
In elderly, normocytic or microcytic anemia deeply influences pa-
tientmortality and quality of life by (i) decreasing physical performance
and cognitive function; and (ii) increasing number of falls and hospital-
ization (Fig. 1) [22,24,48]. IDA and anemia of chronic diseases (or func-
tional ID) are the main causes of anemia in older adult. Although
different factors contribute to ID in elderly patients, malnutrition,
delay gastric emptying and occult blood loss are the main causes of ID
in aged subjects [22,49]. In addition, the decline of biological and cogni-
tive functions associated with reduced appetite and diminish senses of
taste further contribute to inadequate dietary intake and absorption
[22,49]. In this context, the definition of anemia based onHb levels in el-
derly requires a cut-off different from that defined by WHO for adults
[48,50]. Up to now, Hb levels lower than 12 g/dL are commonly consid-
ered indicative of anemia in older adults in both sexes [48,50]. The inter-
pretation of markers of iron status in elderly is complicated by the
presence of concomitant chronic disorders, which might affect serum
ferritin levels and the profile of anemia. Thus, an appropriate cut-off
value for serum ferritinmight be proposed in screening anemia in elder-
ly (Fig. 1 and Table 2). This is in combination with percentage of TS and
CRP allows the identification of IDA and functional ID [48,50].
3.3.4. Gastrointestinal (GI) disorders
In adulthood, different gastrointestinal disorders might be associat-
ed with microcytic anemia due to ID. In men and post-menopausal
women, occult gastrointestinal bleeding accounts for the large part of
IDA (Table 2). In older subjects (1–10% of patients as reported by God-
dard et al.) [51], dual pathologies involving upper and lower GI system
should always be considered during the diagnostic process for IDA.
Malabsorbtion related diseases account for a subset of patients, who
might develop IDA (Table 2). Among them, gastrectomized individuals
require special attention when microcytic anemia is detected, due to
the increase risk of gastric cancer development [51].
Recent studies have linked chronic infection by Helicobacter pylori
(HP) to the development of recurrent IDA (Fig. 1, Table 2) [6,15,52].
The eradication treatment for HP beneficially impacts iron homeostasis,
as supported by the amelioration of ferritin levels. In addition, the pro-
ton pump inhibitors seem not to contribute to the iron deficiency [51].
Inflammatory bowel diseases (IBD) are also characterized by IDA,
which impacts patient QoL (Table 2). Although clinicians are awardedf iron deficiency anemia in adults: Systemic review on advances in
16/j.ejim.2017.04.018
Table 2
Diagnosis and therapeutic options in special subset of patients affected by microcytic anemia related to ID.
Disease Causes of ID Diagnosis Clinical
management
Follow-up Notes Ref.
GI
disorders
Occult blood
loss
Malabsorpition
• NSAID use
• Colon carci-
noma
• Benign gas-
tric ulcer
• Gastric
cancer
• Coelic dis-
ease
• Gastrectomy
• Infection
(HP, Giardia
l.)
Microcytic
anemia
SF b30
ng/mL
TST b 20%
• Remove the
cause
• Oral Fe suppl.
• i.v. Fe suppl is
indicated.
Hb levels after 4 weeks
and then every 3
months the iron related
indices for the first year
then once/y
- Verify tolerability and patient
adherence to oral Fe suppl.
- Consider iv Fe suppl. if failure
after 6 months suppl.
[3,6,15,23,24,25,26,27,28,29]
IBD
(Disease
activity)
• Quiescent D.
• Active D.
Microcytic
anemia
SF b30 μg/L
TST b 20%
Microcytic
anemia
SF b100
ng/mL
TST b 20%
i.v. Fe suppl. is
preferred
Treat the active
IBD
Absolute
indication for i.v.
Fe suppl are:
• Hb b 10 g/dL
• Intolerance to
oral Fe suppl.
• Inadequate re-
sponse to oral
Fe suppl.
• Severe intes-
tine D.
Hb levels after 4 weeks
and then every 3
months the iron related
indices for the first year
then once/y
Microcytic anemia
is still undertreated in IBD
patients
CKD
• Reduced Fe
absorption
related to
chronic in-
flammatory
state
• Relative EPO
deficiency
• Uremic in-
duced inhi-
bition of
erythropoiesis Not yet on HD:
Microcytic anemia
SF b 100 ng/mL TST b
20%
On HD:
Microcytic anemia
SF b 200 ng/mL
Oral Fe suppl.: 30% of pts.
shows GI side effects: consider
i.v. Fe suppl.
i.v. Fe suppl.: well tolerated.
• Hb levels after 4 weeks with 1–
2 g/month increase
• Evaluation of pts QoL improve-
ment
• %hypochromic RBCs
Func-
tional
ID:
Normoc-
ytic
anemia
S-
F:100–8-
00
ng/mL
TST:
N20% [3,30,31,32,33,34,35,36]
Chronic
heart
failure
(CHF)
• Reduced Fe
absorption
related to
chronic in-
flammatory
state
• Nutritional
factors
• Suboptimal
mesenteric
blood flow
SFa b100
ng/mL
SF:100–300
ng/mL and
TST b 20%
i.v. Fe suppl has
to be considered
due to:
• low pts. ad-
herence to
oral therapy
• suboptimal
mesenteric
blood flow (
absorption
and
politherapy)
Hb levels after 4 weeks
and then every 3
months the iron related
indices for the first year
then once/y
In anemic pts consider
Hb target N7 g/dL
ESAs should be considered
only in presence of chronic
renal failure
[3,37,38,39,40,41,42,43,44,45,46,64]
4 L. De Franceschi et al. / European Journal of Internal Medicine xxx (2017) xxx–xxx
Please cite this article as: De Franceschi L, et al, Clinical management of iron deficiency anemia in adults: Systemic review on advances in
diagnosis and treatment, Eur J Intern Med (2017), http://dx.doi.org/10.1016/j.ejim.2017.04.018
Table 2 (continued)
Disease Causes of ID Diagnosis Clinical
management
Follow-up Notes Ref.
Elderly
• Malnutrition
• Delay gastric
emptying
• occult blood
loss
• Presence of
chronic in-
flammatory
diseases
Microcytic
anemia
SF b 30
ng/mL
TST b 20%
Anemia
SF b
30–100
ng/mL,TST
b 20%
CRP
• Identify and
remove the
cause;
• Oral Fe suppl.
fractioned in
small doses.
i.v. Fe suppl. has
to be considered
if:
• GI intolerance
to oral Fe for-
mulation
• GI disorders
• Presence of
co--
morbidities:
CKD, HD, IBD
RBC transfusion
should be
considered if Hb
levels
• b6 g/dL
(acute set-
ting)
• 7–8 g/dL
(chronic
setting)
Hb levels after 4 weeks
and then every 3
months the iron related
indices for the first year
then once/y
Hb target N8 g/dL
- Functional ID as
normocytic anemia:
• SF: N100 ng/mL
• TST: N20%
• CRP
- Unexplained normochromic
normocytic hypoproliferative
anemia, possibly related to
stem cell disorder(s) and
characterized by:
• CRP
[3,22,47,48,49,50]
IRIDA Autosomal
recessive
condition
Mutations in
TMPRSS6 gene
Microcytic
anemia
SF ≥ 30
ng/mL
TST b 20%
Oral Fe suppl.:
high possibility
of failure
Consider i.v. Fe
suppl.
Hb levels after 4 weeks
and then every 3
months the iron related
indices for the first year
then once/y
Hamp
[5,6,9,12,13,15]
NSAID: non steroid anti-inflammatory drug; IBD: inflammatory bowel disease; CHF: chronic heart failure; IRIDA: iron refractory iron deficiency anemia; SF: serum ferritin; TST: transferrin
saturation; ESAs: erythropoietic stimulating agents; pts.: patients; QoL: quality of life; RBCs: red blood cells; Hamp: hepcidin; suppl: supplementation.
a The cut-off for SFwithout transferrin saturation has been selected by Task force for diagnosis and treatment of acute and chronic heart failure of the European society of cardiology and
by the American college of physician.
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[23,51,53–56]. IDA in presence of active IBD requires the combined
therapeutic approach of primary disease treatment and ID correction.
3.3.5. Iron restricted iron deficiency anemia (IRIDA)
IRIDA is the most common inherited condition of iron metabolism
characterized bymicrocytic anemia (Tables 1, 2). IRIDA is causedbymu-
tations in TMPRSS6 gene. Usually MCV is lower than in the other condi-
tions of IDA and transferrin saturation is always very low with low/
normal serum ferritin (Tables 1, 2). Hamp levels are either normal or in-
creased compared to healthy subjects. RCP is negative and this allows
the physician to differentiate it from ACD. IRIDA generally should be
suspected in presence of recurrent IDA with unexplained causes, char-
acterized by several failures of oral iron supplementation (Fig. 1) [9,
12,13].
3.4. Major advances in treatments of IDA
Being ID themain cause ofmicrocytic anemia in patients admitted to
Internal Units, the treatment is based on iron supplementation, as oral
iron or intravenous iron administration (Table 3). The choice on iron
supplementation is based onHb levels, the tolerance to oral iron supple-
mentation and the presence of concomitant disease, whichmight affect
iron absorption (Table 3). The failure of oral iron supplementation
might be related to either low patient adherence to the therapy (i.e.:Please cite this article as: De Franceschi L, et al, Clinical management o
diagnosis and treatment, Eur J Intern Med (2017), http://dx.doi.org/10.10treatment discontinuation, low tolerance mainly due to GI symptoms)
or to true refractoriness (Fig. 1 and Table 3) [5,6,14,23,25,57–62].
Since Hamp plays a key role in iron absorption and homeostasis, differ-
ent studies have evaluated Hamp response to acute oral iron supple-
mentation. Morretti et al. have recently showed that 48 h are required
to clear the effect of Hamp release in response to acute oral iron admin-
istration [57]. This study supports the introduction of alternative day
schedule in place of daily administration of oral iron to overcome the
Hampmediated block of iron absorption. Thismight ameliorate iron ab-
sorption and improves patient tolerability to oral iron supplementation
(Table 3). Oral iron supplementation should be maintained for 3 to
6 months to replete the iron stores and normalize ferritin level.
Intravenous iron administration is definitively more effective in cor-
rection of ID since it by-passes the iron absorption step. Although its
costs are higher than oral iron supplementation, it offers several advan-
tages such as (i) rapid repletion of iron stores; (ii) single dose sufficient
for most of the new i.v. formulation with a reduction in hospital visits
(Table 3) [6,63]. This latter is limited to the more recently developed
molecules, which are characterized by a core that contains the iron
salt surrounded by a shell, allowing the reticuloendothelial system to
process and release iron for erythropoiesis and storage (Table 3) [5,6,
14,23,25,57–62]. Although adverse events have been reported for i.v.
formulation, the cost-benefit ratio is in favor of i.v. supplementation as
also indicated by the European Medicines Agency (EMEA: http://
www.emea.europe.eudocument WC500150771, 2013), introducingf iron deficiency anemia in adults: Systemic review on advances in
16/j.ejim.2017.04.018
Table 3
Major iron formulations available and current treatments for ID.
Treatment Agent Dosage Amount of Fe
administrated
(mg)
Adverse events Recommendations Ref.
Oral iron
suppl.
Ferrous
Ssulphate
1
tablet/day
(Fe2+)
85–105 mg
• Nausea
• Vomit
• Epigastric disconfort
• Constipation/diarrhoea
• Metallic taste
• Dark colored stools
• Healthy popula-
tion after treat-
ment of
underlying cause
of IDA;
• Elderly if Hb
N 8 g/dL b 12 g/dL;
Gray area:
Every day or
alternative day
schedule.
[3,5,6,14,26,51,52,53,54,56,60]
Ferrous
gluconate
1
tablet/day
(Fe2+) 75–80
mg
Na+
ferrigluconate
1 fl/day (Fe3+) 62.5
mg
Fe-glycine
sulphate
1
tablet/day
(Fe2+) 100
mg
Fe-bisglycinate 1–3
tablet/day
(Fe2+) 25 mg
Lyposomial
Fe-pyroph and
Vit. C
1–2
tablet/day
(Fe2+) 30 mg
and
Vit. C 70 mg
I.v. Iron
suppl.
Na+
ferrigluconate
1–2
fl/day-
diluted in
FS
(Fe3+) 62.5
mg
• Nausea
• Vomit
• Pruritus
• Headache and flushing
• Myalgia and arthralgia
• Back and chest pain (res-
olution within 48 h)
Notes
• Avoid iv Fe suppl. during
the first trimester of preg-
nancy (no data available
on safety)
• Test-dose is NOT informa-
tive on possible severe
AEs.
Strong indication in:
• CKD stage 5D
• IBD with active
disease
• Malabsorption
• CHF
• Hb ≤8 g/dL
• IRIDA
• IDA with intoler-
ance to oral Fe
suppl.
Suggested in:
• CKD stage 3D-5D
Gray area:
IDA in elderly
[3,5,6,13,14,26,31,36,51,52,53,54,55,56,57,58,59,61,62,63,64]
Ferric
carboximaltoside
500–1000
mg
diluted in
SS
(Fe3+)
100–500 mg
Fe-saccharate 1 fl/day
diluted in
SS
(Fe3+) 100
mg
Ferumoxytol 510 mg (Fe3+) 510
mg
Vit.C: Vitamine C; fl: SS: saline solution; i.v.: intravenous; CKD: chronic kidney disease; CHF: chronic heart failure; IBD: inflammatory bowel disease; Hb: hemoglobin; IDA: iron deficiency
anemia; Hamp: hepcidin; IRIDA: iron refractory iron deficiency anemia; hrs: hours; D: disease; suppl: supplementation.
Ganzoni formula calculates the amounts of iron required to restore desireHb levels: iron deficit (mg)= bodyweight (Kg)× (target Hb-actual Hb) (g/dL) × 2.4+ iron storage depot (mg).
6 L. De Franceschi et al. / European Journal of Internal Medicine xxx (2017) xxx–xxxstrategies to minimize adverse events [64]. A large revision of the liter-
ature on the safety of different iron i.v. formulations has concluded that
i.v. iron therapy is not associated with increased risk of severe adverse
events (AEs), even in patients with history of heart failure or of infec-
tions [62].
The follow-up schedule of iron-supplementation therapy is based on
the evaluation of Hb levels at 4weeks of treatment. Recently, the day-14
Hb levels have been proposed in decision-making process to move pa-
tient from oral to i.v. administration in case of failure [14].
In special subset of patients such as elderly, CKD, IBD and CHF sub-
jects, rapid correction of IDA is important and generally required an in-
tensive therapeutic approach with maximized tolerability (Table 3).
IBD patients with quiescent disease generally feel uncomfortable
with oral iron supplementation mainly due GI AEs [54,65]. Thus, i.v.
route should be preferred in IBD patients, according to the available
guidelines (Table 3) [23,51,53–56].
In CKD, iron oral supplementation is recommended in patients with
IDA not receiving ESAs and not on HD [66]. Whereas, i.v. iron should be
proposed to subjects under ESAs treatment and/or on HD, based on the
evidence that oral iron does not sufficiently support ESAs stimulated
erythropoiesis [31,36,67,68]. Up to now it is still not clear whether the
high dose low frequency or low dose high frequency strategy might
be the best option in these patients [31,36,67,68]. In addition, frequent
re-evaluation of SF and TST combined with Hb levels should always be
carried out to avoid iron-overload, which has been recently reported
in CKD subjects longtime treated with i.v. iron supplementation [31].Please cite this article as: De Franceschi L, et al, Clinical management o
diagnosis and treatment, Eur J Intern Med (2017), http://dx.doi.org/10.10In subjectswith CHF, iron supplementation and correction of anemia
improve (i) New York Heart Association (NYHA) functional classes; (ii)
exercise capacity and (iii) patients QoL [42–44,69]. Thus, iron supple-
mentation should be always considered as part of clinical management
of CHF patients.
In elderly, IDA affects QL, cognitive function and worsened chronic
organ diseases, deeply affecting patient mortality and morbidity [3,34,
59,70]. Thus, iron supplementation has to be introduced in these pa-
tients. However, it should be always considered the final objective of
this treatment and the cost/benefit ratio of iron supplementation in
elderly.
In IRIDA patients, oral iron administration usually does not solve the
problem, whereas i.v. iron temporally ameliorate this condition. Ferritin
levels could be reduced or normal after iron treatment [6,13].
3.5. Areas of uncertainty
In adult patients admitted to InternalMedicine setting, the diagnosis
and the management of IDA should receive great attention and be con-
sidered as target of intervention. However, various aspects of IDA treat-
ment and route of administration in different subset of patients are still
uncertain. In elderly, large clinical trials to better identify thefinal objec-
tives of the iron supplementation and the route of administration (oral
or i.v.) are needed. The lack of general recommendation in these fragile
patients might result in under-treatment of IDA. In CHF subjects, the re-
cent guidelines propose the use of i.v. iron supplementation in patientsf iron deficiency anemia in adults: Systemic review on advances in
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dation is based on clinical trials [42–44], although no data are available
on the timing and duration of iron supplementation.
In patients with anemia related to chronic diseases (ACD), it is cru-
cial the identification of absolute ID, since ID is often functional. In
ACD, the clinical management of absolute ID is still largely a physician
choice, which is based on patient clinical status, clinical stage of the dis-
ease especially for cancers as well as the cost/benefits ratio [71].
Since one the main are of uncertainty is the treatment of fragile pa-
tient further work is required to better define the route of administra-
tion of iron supplementation and the therapeutic endpoints of iron
supplementation.
4. Discussion
Functional or absolute iron deficiency associated with microcytic
anemia is common in adult patients in Internal medicine setting. This
is especially true for fragile patients such as subjects with IBD, CKD,
CHF and in elderly. Global burden studies reveled that ID is one of the
top cause-specific anemia burden, representing a target of intervention
for both physician and national-international health programs.
Although progresses in pathogenesis anddiagnosis of IDA have ame-
liorated in the last decades, the decision-making processes facing IDA
still requires a comprehensive patient evaluation and cost/benefit
estimation.
This review has some limitations since we excluded children and
fertile women with IDA due to gynecologic or obstetric causes (i.e. ma-
ternal hemorrhage and/or menometrorrhagia), who represent a large
portion of IDA in adulthood [1].
Finally, in Internal Medicine Units, a large part of patients is repre-
sented by fragile subset. They require a rapid identification of the causes
underlying IDA and a specific treatment to improve their outcomes.
Concerning the out-patients with recurrent unexplained IDA, more
rare condition of IDA related to inherited disorder or GI infections or au-
toimmune gastrite should always be considered and excluded.
The improvement of iron preparations for i.v. supplementation, have
impacted: (i) the safety; (ii) the patient satisfaction; (iii) the health
costs by reducing the number of hospital visits; and the in-stay hospital
(iv) the welfare spending by the reduction of patient disability and the
level of sickness absence from jobs. Thus, special program of interven-
tion should be designed and set-up at national and international level
to early identify and treat microcytic anemia related to ID.
5. Conclusions
In internal medicine setting adult patients are characterized by
multimorbidity and poli-pharmacologic treatments, whichmight affect
the erythropoietic compartment, contributing to anemia and iron defi-
ciency. The early identification the underlying causes of IDA may lead
to a target therapeutic approach, combined with iron supplementation.
Fragile patients such as subjects with IBD, CKD, CHF and elderly repre-
sent a growing population requiring early and special care attention.
Multicentric trials in subsets of adult fragile patients are needed to get
important information useful in clinical practice. Although recommen-
dation and guidelines are important in decision-making process, these
authors strongly suggest that a reasoned and personalized medical
treatment focused on each patient clinical profile is the most powerful
approach to iron deficiency anemias.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ejim.2017.04.018.
Learning points
• Global burden disease studies show that iron deficient anemia
(IDA) is one the main cause of increased years-life lived-with-dis-
ability (YLD) in all ages and both sex.Please cite this article as: De Franceschi L, et al, Clinical management o
diagnosis and treatment, Eur J Intern Med (2017), http://dx.doi.org/10.10• IDA affects a large part of adult and elderly patients admitted to Inter-
nal Medicine Units.
• The available evidences indicate that (i) recurrent IDA should always
be investigated, considering uncommon causes; (ii) IDA might worse
the performance and the clinical outcome of fragile and high-risk pa-
tients and might require an intensive treatment.
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